Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HMGCR | P04035 | 2/20 | 1.00 |
| ▸ | SLCO1B1 | Q9Y6L6 | 2/20 | 1.00 |
| ▸ | ABCB1 | P08183 | 1/20 | 1.00 |
| ▸ | ABCC2 | Q92887 | 1/20 | 1.00 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.58 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.58 |
| ▸ | RHOC | P08134 | 1/20 | 0.58 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.58 |
| ▸ | THRB | P10828 | 1/20 | 0.58 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.58 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.58 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.58 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.58 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Atorvastatin Lactone SCHEMBL13762456 | 1.00 | HMGCR (1.00) | HMGCRSLCO1B1ABCB1ABCC2NR1I2 | |
| Atorvastatin Lactone SCHEMBL1266 | 1.00 | HMGCR (1.00) | HMGCRSLCO1B1ABCB1ABCC2NR1I2 | |
| Atorvastatin Lactone SCHEMBL1258955 | 1.00 | HMGCR (1.00) | HMGCRSLCO1B1ABCB1ABCC2NR1I2 | |
| Atorvastatin Lactone SCHEMBL12060138 | 1.00 | HMGCR (1.00) | HMGCRSLCO1B1ABCB1ABCC2NR1I2 | |
| Atorvastatin Lactone SCHEMBL1265 | 1.00 | HMGCR (1.00) | HMGCRSLCO1B1ABCB1ABCC2NR1I2 | |
| Atorvastatin Lactone SCHEMBL10025147 | 1.00 | HMGCR (1.00) | HMGCRSLCO1B1ABCB1ABCC2NR1I2 | |
| Atorvastatin Lactone SCHEMBL9810905 | 0.97 | HMGCR (0.94) | HMGCRSLCO1B1ABCB1ABCC2NR1I2 | |
| SCHEMBL5605464 | 0.96 | HMGCR (0.93) | HMGCRSLCO1B1ABCB1ABCC2NR1I2 | |
| SCHEMBL5605468 | 0.96 | HMGCR (0.93) | HMGCRSLCO1B1ABCB1ABCC2NR1I2 | |
| SCHEMBL13992376 | 0.96 | HMGCR (0.93) | HMGCRSLCO1B1ABCB1ABCC2NR1I2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9585964-B2 | Liver targeted conjugates | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2017-03-07 | — | — | US | disclosed |
| US-20130245101-A1 | Liver Targeted Conjugates | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2013-09-19 | — | — | US | disclosed |
| EP-2405911-B1 | USE OF ATORVASTATIN LACTOLS AS MEDICAMENTS | REDX PHARMA LTD (GB) | 2013-03-06 | — | — | EP | disclosed |
| US-20110124704-A1 | DEUTERIUM-ENRICHED ATORVASTATIN | PROTIA, LLC (US) | 2011-05-26 | — | — | US | disclosed |
| US-20100222405-A1 | MAGNESIUM SALTS OF HMG-COA REDUCTASE INHIBITORS | RANBAXY LABORATORIES LIMITED (IN) | 2010-09-02 | — | — | US | disclosed |
| US-20100222405-A1 | MAGNESIUM SALTS OF HMG-COA REDUCTASE INHIBITORS | RANBAXY LABORATORIES LIMITED (IN) | 2010-09-02 | — | — | US | disclosed |
| US-7745480-B2 | Deuterium-enriched atorvastatin | PROTIA, LLC (US) | 2010-06-29 | — | — | US | disclosed |
| US-20090216029-A1 | PROCESS FOR THE PRODUCTION OF ATORVASTATIN CALCIUM IN AMORPHOUS FORM | RANBAXY LABORATORIES LIMITED (IN) | 2009-08-27 | — | — | US | disclosed |
| US-RE40667-E1 | [R-(R*R*)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid, its lactone form and salts thereof | WARNER-LAMBERT COMPANY LLC (US) | 2009-03-17 | — | — | US | disclosed |
| US-20080280970-A1 | DEUTERIUM-ENRICHED ATORVASTATIN | PROTIA, LLC | 2008-11-13 | — | — | US | disclosed |
| US-20080280971-A1 | deuterated (3R,5R)-7-[2-(4-fluorophenyl)-3-phenyl-4-(phenylcarbamoyl)-5-propan-2-ylpyrrol-1-yl]-3,5-dihydroxyheptanoic acid, used for the treatment of dyslipidemia and/or hyperlipemia | PROTIA, LLC (US) | 2008-11-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130245101-A1 | Liver Targeted Conjugates | LDLR, HMGCR, FABP1 | HMGCR 2/4885SLCO1B1 474/4885ABCB1 23/4885 |
| US-20090216029-A1 | PROCESS FOR THE PRODUCTION OF ATORVASTATIN CALCIUM IN AMORPHOUS FORM | HMGCR, CACYBP, SARAF | HMGCR 1/4885SLCO1B1 433/4885ABCB1 2670/4885 |
| US-20080280971-A1 | deuterated (3R,5R)-7-[2-(4-fluorophenyl)-3-phenyl-4-(phenylcarbamoyl)-5-propan-2-ylpyrrol-1-yl]-3,5-dihydroxyheptanoic acid, used for the treatment of dyslipidemia and/or hyperlipemia | PCSK9, DHCR7, HMGCR | HMGCR 3/4885SLCO1B1 1352/4885ABCB1 1594/4885 |
| US-20100222405-A1 | MAGNESIUM SALTS OF HMG-COA REDUCTASE INHIBITORS | HMGCR, CYP11A1, DHCR7 | HMGCR 1/4885SLCO1B1 558/4885ABCB1 312/4885 |
| US-20110124704-A1 | DEUTERIUM-ENRICHED ATORVASTATIN | HMGCR, PCSK9, STARD3 | HMGCR 1/4885SLCO1B1 340/4885ABCB1 3015/4885 |
| US-20080280970-A1 | DEUTERIUM-ENRICHED ATORVASTATIN | HMGCR, PCSK9, STARD3 | HMGCR 1/4885SLCO1B1 340/4885ABCB1 3015/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.